Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma - European Medical Journal

Continue

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD, PhD, from National Cancer Center Hospital East, Kashiwa, Japan, discusses the progression-free survival and response rates in pre-defined subgroups and biomarker-defined populations in LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given